SS Innovations International (NASDAQ: SSII) is solidifying its position in the emerging field of telerobotic surgery, according to a recent MedTech Dive report. The company's SSi Mantra system has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. This milestone underscores the growing viability of remote surgery, which allows surgeons to operate on patients from miles away using robotic technology.
In an interview with MedTech Dive, SS Innovations CEO Dr. Sudhir Srivastava, a cardiac surgeon, emphasized that robotic surgery is inherently a form of teleoperation. He noted that the critical technical challenge is determining how much distance can be introduced without compromising the system's responsiveness. The SSi Mantra system appears to be addressing this challenge effectively, as evidenced by its expanding clinical use. The company's installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503.
The implications of this growth are significant. Telerobotic surgery has the potential to democratize access to specialized surgical care, bringing expert surgeons to remote or underserved regions without the need for travel. SS Innovations has already expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. These initiatives demonstrate the global demand for advanced robotic surgery solutions and the company's ability to execute on its international strategy.
Regulatory milestones are also on the horizon. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking, which would open the door to two of the world's largest healthcare markets. Achieving these certifications would not only validate the safety and efficacy of the SSi Mantra system but also position the company to compete with larger medical-device players. For investors, this represents a substantial growth opportunity, as the global surgical robotics market continues to expand.
The recent MedTech Dive article, which highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers, can be accessed at https://ibn.fm/4ZLvL. The report examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery, providing context for why SS Innovations' progress matters. As telerobotic surgery gains ground, the company's early experience and expanding installed base could give it a competitive edge.
For those following the company, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Additionally, more information about SS Innovations International (NASDAQ: SSII) can be found at SS Innovations International (NASDAQ: SSII). The full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published, are available at https://IBN.ai/Disclaimer.
The broader significance of SS Innovations' advancements lies in the transformation of surgical care delivery. Telerobotic surgery could reduce disparities in access to high-quality surgical expertise, particularly in regions with limited healthcare infrastructure. Moreover, the technology has implications for emergency response, military medicine, and space exploration, where remote surgical capabilities could be life-saving. As SS Innovations continues to accumulate clinical experience and pursue regulatory approvals, it is helping to shape the future of surgery—one that is increasingly remote, precise, and accessible.
